B cell activation is central in the disease mechanism of SLE, as it is characterized by the production of autoantibodies against conserved cellular components including double-stranded DNA (dsDNA) (58–70% of SLE patients [3,6]), histones, Ro52, Ro60, La and Sm [4,6–8]. The gene discussed is TRIM21; the disease is systemic lupus erythematosus.